Exploring a new treatment for lung cancer with KEAP1 mutations
Official title: Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer
Funded at New York University School of Medicine · NIH-11002314 · Data updated 2026-11-12
This study is looking at a new treatment for lung cancer that targets a specific part of the cancer cells in patients with certain genetic changes, to see if it can help slow down tumor growth and find out which patients might benefit the most.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 19, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $655,478 |
| NIH project number | 5R01CA262562-02 |
| Project ID | NIH-11002314 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KRAS-driven lung adenocarcinoma who also have KEAP1 mutations.
✕Less likely to help
Patients without KRAS mutations or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates a novel glutamine antagonist as a potential treatment for lung cancer patients with specific KEAP1 mutations. By using advanced genetic editing techniques, the study aims to understand how these mutations affect cancer cell metabolism and how targeting glutamine can inhibit tumor growth. The research will involve both human and mouse models to assess the effectiveness of this new therapy and identify which patients may benefit the most from it. The goal is to provide a more tailored approach to treating lung cancer based on genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KEAP1 mutant lung cancer.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant results.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Papagiannakopoulos, Thales — New York University School of Medicine
- Study coordinator: Papagiannakopoulos, Thales
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.